In the latest versions of the NCCN Clinical Practice Guidelines and ESMO Clinical Practice Guidelines, both TGET and FGET are recommended for the first-line treatment of EGFR-mutated advanced NSCLC 4,13. Here, EGFR is linked to non-small cell lung carcinoma.